What is Experimur?
Experimur operates as a specialized toxicology testing and research laboratory, offering extensive experience in conducting a wide array of pre-clinical (non-clinical) and regulatory toxicology studies. Their expertise spans from chronic and acute testing to specialized areas such as teratology, reproduction, pharmacokinetics, and neurotoxicity. The company adheres strictly to FDA, EPA, and OECD testing guidelines and Good Laboratory Practices (GLPs), ensuring the highest standards of scientific rigor and regulatory compliance in its services.
How much funding has Experimur raised?
Experimur has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$737K
Debt (2020): $350K with participation from PPP
Debt (2021): $737K led by PPP
Key Investors in Experimur
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Experimur?
The recent major strategic investment signifies a strong vote of confidence in Experimur's business model and its capacity for growth within the highly regulated field of toxicology. This infusion of capital is expected to fuel further development of its specialized testing capabilities, potentially enabling the company to expand its service offerings, enhance its research infrastructure, and broaden its market reach. The company's focus on compliance and specialized studies positions it to capitalize on increasing demand for reliable pre-clinical data in drug development and chemical safety assessments.
See full Experimur company page
